Research & Literature

Malignant lymphoma of the conjunctiva.

Kirkegaard MM, Coupland SE, Prause JU, Heegaard S

Survey of ophthalmology 2015; (60(5)):444-58.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Pastore A, Jurinovic V, Kridel R, et al.

The Lancet. Oncology 2015; (16(9)):1111-1122 doi:10.1016/S1470-2045(15)00169-2.

Classification of follicular lymphoma: the effect of computer aid on pathologists grading.

Fauzi MF, Pennell M, Sahiner B, et al.

BMC medical informatics and decision making 2015; (15()):115 doi:10.1186/s12911-015-0235-6.

Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.

Yang D, Fu X, Zhang X, et al.

Oncology letters 2015; (10(5)):3261-3265 doi:10.3892/ol.2015.3703.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.

Maeng CH, Ahn SW, Ryu SY, et al.

The Korean journal of internal medicine 2016; (31(3)):560-9 doi:10.3904/kjim.2014.222.

Is watch and wait still acceptable for patients with low-grade follicular lymphoma?

Armitage JO, Longo DL

Blood 2016; (127(23)):2804-8 doi:10.1182/blood-2015-11-632745.

Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.

Schmidt J, Gong S, Marafioti T, et al.

Blood 2016; (128(8)):1101-11 doi:10.1182/blood-2016-03-703819.

Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.

Sugimoto T, Watanabe T

Journal of clinical and experimental hematopathology : JCEH 2016; (56(1)):1-19 doi:10.3960/jslrt.56.1.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

Jurinovic V, Kridel R, Staiger AM, et al.

Blood 2016; (128(8)):1112-20 doi:10.1182/blood-2016-05-717355.

Prevalence of BCL-2/J(H) Translocation in Healthy African Americans.

Colon-Otero G, Van Wier SA, Ahmann GJ, et al.

Annals of hematology 2017; (96(1)):51-55 doi:10.1007/s00277-016-2842-4.

Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary Care Institute in Southern India.

Sylvia MT, Dey B, Basu D, et al.

Mediterranean journal of hematology and infectious diseases 2016; (8(1)):e2016060 doi:10.4084/MJHID.2016.060.

[Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].

Xu PP, Qian Y, Chen QS, et al.

Zhongguo shi yan xue ye xue za zhi 2017; (25(2)):426-430 doi:10.7534/j.issn.1009-2137.2017.02.021.

Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.

Verriere B, Gastaud L, Chamorey E, et al.

Hematological oncology 2018; (36(1)):144-149 doi:10.1002/hon.2458.

Transformed follicular lymphoma.

Fischer T, Zing NPC, Chiattone CS, et al.

Annals of hematology 2018; (97(1)):17-29 doi:10.1007/s00277-017-3151-2.

PET/CT for Staging; Past, Present, and Future.

El-Galaly TC, Gormsen LC, Hutchings M

Seminars in nuclear medicine 2018; (48(1)):4-16 doi:10.1053/j.semnuclmed.2017.09.001.

Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions.

Morkel M, Ellmann A, Warwick J, Simonds H

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2018; (28(2)):379-384 doi:10.1097/IGC.0000000000001174.

Pathogenesis of follicular lymphoma.

Lackraj T, Goswami R, Kridel R

Best practice & research. Clinical haematology 2018; (31(1)):2-14 doi:10.1016/j.beha.2017.10.006.

Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT.

Mustafa M, Patel D, Shen L, et al.

Tomography (Ann Arbor, Mich.) 2018; (4(1)):1-3 doi:10.18383/j.tom.2017.00022.

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.

Hellmuth JC, Louissaint A, Szczepanowski M, et al.

Blood 2018; (132(16)):1695-1702 doi:10.1182/blood-2018-03-837252.

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

Musilova K, Devan J, Cerna K, et al.

Blood 2018; (132(22)):2389-2400 doi:10.1182/blood-2018-06-855502.

Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.

Hutchings M

Cancer journal (Sudbury, Mass.) 2018; (24(5)):215-222 doi:10.1097/PPO.0000000000000336.

Fear of Cancer Recurrence: A Systematic Review of Randomized, Controlled Trials.

Chen D, Sun W, Liu N, et al.

Oncology nursing forum 2018; (45(6)):703-712 doi:10.1188/18.ONF.703-712.

Where to start? Upfront therapy for follicular lymphoma in 2018.

Leonard JP, Nastoupil LJ, Flowers CR

Hematology. American Society of Hematology. Education Program 2018; (2018(1)):185-188 doi:10.1182/asheducation-2018.1.185.

[Pathological features of duodenal-type follicular lymphoma].

Zhang F, Luo DL, Chen Y, et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology 2019; (48(1)):22-25 doi:10.3760/cma.j.issn.0529-5807.2019.01.005.

How I treat early-relapsing follicular lymphoma.

Casulo C, Barr PM

Blood 2019; (133(14)):1540-1547 doi:10.1182/blood-2018-08-822148.

[Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy].

Wang N, Xu PP, Wang L, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(1)):46-51 doi:10.3760/cma.j.issn.0253-2727.2019.01.009.

Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma.

Feugier P, Filliatre-Clement L

F1000Research 2019; (8()) doi:10.12688/f1000research.16686.1.

Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.

Al-Juhaishi T, Khurana A, Shafer D

Best practice & research. Clinical haematology 2019; (32(1)):47-53 doi:10.1016/j.beha.2019.02.008.

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.

Gibiansky E, Gibiansky L, Buchheit V, et al.

British journal of clinical pharmacology 2019; (85(9)):1935-1945 doi:10.1111/bcp.13974.

One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?

Roschewski M, Hill BT

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019; (39()):467-476 doi:10.1200/EDBK_239065.

Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.

Boughan KM, Caimi PF

Current oncology reports 2019; (21(7)):63 doi:10.1007/s11912-019-0808-0.

Diagnosis and management of follicular lymphoma: A comprehensive review.

Dada R

European journal of haematology 2019; (103(3)):152-163 doi:10.1111/ejh.13271.

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.

Freeman CL, Kridel R, Moccia AA, et al.

Blood 2019; (134(9)):761-764 doi:10.1182/blood.2019000258.

High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia.

Rogers TS, Gardner JA, Devitt KA

Autopsy & case reports 2019; (9(3)):e2019090 doi:10.4322/acr.2019.090.

Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.

Johns SA, Stutz PV, Talib TL, et al.

Cancer 2020; (126(1)):211-218 doi:10.1002/cncr.32518.

Impact of fear of cancer recurrence on survival among lymphoma patients.

Kim SJ, Kang D, Kim IR, et al.

Psycho-oncology 2020; (29(2)):364-372 doi:10.1002/pon.5265.

Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review).

Zhu Z, Li T, Zhang X, et al.

International journal of oncology 2020; (56(1)):7-17 doi:10.3892/ijo.2019.4917.

A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

Makita S, Maruyama D, Maeshima AM, et al.

Asia-Pacific journal of clinical oncology 2020; (16(3)):108-114 doi:10.1111/ajco.13248.

A man in his forties with increasing shortness of breath.

Tveiten H, Lehne G, Aukrust P, et al.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2020; (140(6)) doi:10.4045/tidsskr.19.0692.

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.

Kim YR, Kim SJ, Cheong JW, et al.

The Korean journal of internal medicine 2021; (36(Suppl 1)):S245-S252 doi:10.3904/kjim.2019.376.

Initial Treatment of High Tumor Burden Follicular Lymphoma.

Freeman CL, Sehn LH

Hematology/oncology clinics of North America 2020; (34(4)):673-687 doi:10.1016/j.hoc.2020.02.004.

Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.

Okosun J, Montoto S

Hematology/oncology clinics of North America 2020; (34(4)):701-714 doi:10.1016/j.hoc.2020.02.006.

Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.

Chin CK, Nastoupil LJ

Hematology/oncology clinics of North America 2020; (34(4)):743-756 doi:10.1016/j.hoc.2020.03.002.

Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.

Shahar N, Larisch S

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020; (52()):100712 doi:10.1016/j.drup.2020.100712.

[Clinicopathological characteristics of pediatric-type follicular lymphomas: an analysis of 37 cases].

Zheng YY, Xie JL, Zhang YL, Zhou XG

Zhonghua bing li xue za zhi = Chinese journal of pathology 2020; (49(7)):681-685 doi:10.3760/cma.j.cn112151-20200214-00096.

[Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].

Teramoto M, Sone T, Takada K, et al.

[Rinsho ketsueki] The Japanese journal of clinical hematology 2020; (61(6)):598-604 doi:10.11406/rinketsu.61.598.

Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.

Bitansky G, Avigdor A, Vasilev E, et al.

Leukemia & lymphoma 2020; (61(11)):2645-2651 doi:10.1080/10428194.2020.1786554.

Dramatic radiotherapy response in a necrotic lymphoma mass: a case report.

McNeil N, Gorayski P, Blunt D, Roos D

Journal of medical case reports 2020; (14(1)):118 doi:10.1186/s13256-020-02438-1.

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG.

Pan Q, Luo Y, Zhang Y, et al.

EJNMMI research 2020; (10(1)):89 doi:10.1186/s13550-020-00681-7.

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.

Vogelsberg A, Steinhilber J, Mankel B, et al.

Haematologica 2021; (106(10)):2673-2681 doi:10.3324/haematol.2020.254854.

Transformed lymphoma: what should I do now?

Smith S

Hematology. American Society of Hematology. Education Program 2020; (2020(1)):306-311 doi:10.1182/hematology.2020000115.

Targeted Treatment of Follicular Lymphoma.

Nath K, Gandhi MK

Journal of personalized medicine 2021; (11(2)) doi:10.3390/jpm11020152.

Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.

Wenge DV, Wethmar K, Mikesch JH, et al.

Leukemia & lymphoma 2021; (62(8)):1930-1939 doi:10.1080/10428194.2021.1894645.

Primary cutaneous follicle center lymphoma with extensive plasmacytic differentiation and t(14;18) in both the lymphoid and plasma cell components.

Kelley JT, Brown NA, Hristov AC, Bresler SC

Journal of cutaneous pathology 2021; (48(7)):969-974 doi:10.1111/cup.14020.

When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.

Nastoupil LJ

Current hematologic malignancy reports 2021; (16(1)):45-51 doi:10.1007/s11899-021-00617-5.

Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma.

Ellis S, Brown RF, Thorsteinsson EB, et al.

Psychology, health & medicine 2022; (27(8)):1649-1660 doi:10.1080/13548506.2021.1913756.

The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.

Watanabe T

International journal of molecular sciences 2021; (22(10)) doi:10.3390/ijms22105352.

Endosonography-Guided Biopsy as a First Test in the Diagnosis of Lymphoma.

Dayan G, Soder S, Godin A, et al.

Seminars in thoracic and cardiovascular surgery 2022; (34(3)):1102-1109 doi:10.1053/j.semtcvs.2021.06.010.

Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.

Mou E, Falchi L, Sundaram V, et al.

Leukemia & lymphoma 2021; (62(12)):2864-2872 doi:10.1080/10428194.2021.1941936.

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.

Arushi Khurana , Mwangi R, Ansell SM, et al.

Blood cancer journal 2021; (11(7)):133 doi:10.1038/s41408-021-00525-0.

Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.

Juweid ME, Mueller M, Alhouri A, et al.

Cancer 2021; (127(20)):3727-3741 doi:10.1002/cncr.33772.

Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.

Murakami H, Yoshioka T, Moriyama T, et al.

Acta medica Okayama 2021; (75(4)):461-469 doi:10.18926/AMO/62398.

Psychometric evaluation of the Fear of Cancer Recurrence Inventory (FCRI) and development of a short version in patients with follicular lymphoma.

Xu RH, Yu S, Yang Y, et al.

Disability and rehabilitation 2022; (44(24)):7508-7515 doi:10.1080/09638288.2021.1985631.

[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].

Vogelsberg A, Steinhilber J, Mankel B, et al.

Der Pathologe 2021; (42(Suppl 2)):122-128 doi:10.1007/s00292-021-01011-x.

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.

Fowler NH, Dickinson M, Dreyling M, et al.

Nature medicine 2022; (28(2)):325-332 doi:10.1038/s41591-021-01622-0.

Follicular lymphoma: updates for pathologists.

Khanlari M, Chapman JR

Journal of pathology and translational medicine 2022; (56(1)):1-15 doi:10.4132/jptm.2021.09.29.

Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.

Paszkiewicz-Kozik E, Debowska M, Jakacka N, et al.

Chemotherapy 2022; (67(4)):201-210 doi:10.1159/000523921.

Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma.

Blanco M, Collazo-Lorduy A, Yanguas-Casás N, et al.

Cancers 2022; (14(9)) doi:10.3390/cancers14092158.

Structural Details of BH3 Motifs and BH3-Mediated Interactions: an Updated Perspective.

Sora V, Papaleo E

Frontiers in molecular biosciences 2022; (9()):864874 doi:10.3389/fmolb.2022.864874.

Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.

Cohen JA, Ghobadi A

Expert review of anticancer therapy 2022; (22(9)):903-914 doi:10.1080/14737140.2022.2096009.

[Standard treatment and future perspectives for follicular lymphoma].

Kameoka Y

[Rinsho ketsueki] The Japanese journal of clinical hematology 2022; (63(9)):1135-1144 doi:10.11406/rinketsu.63.1135.

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis.

Lee YP, Lee MS, Yoon SE, et al.

Journal of oncology 2022; (2022()):2263217 doi:10.1155/2022/2263217.

Ascites as First Atypical and Only Clinical Manifestation of De Novo Follicular Lymphoma.

Zdravkovic ND, Grbovic VM, Vojinovic RH, et al.

Medicina (Kaunas, Lithuania) 2022; (58(10)) doi:10.3390/medicina58101381.

Therapeutic intervention in fear of cancer recurrence in adult oncology patients: a systematic review.

Paperák P, Javůrková A, Raudenská J

Journal of cancer survivorship : research and practice 2023; (17(4)):1017-1035 doi:10.1007/s11764-022-01277-x.

Follicular lymphoma and marginal zone lymphoma: how many diseases?

Laurent C, Cook JR, Yoshino T, et al.

Virchows Archiv : an international journal of pathology 2023; (482(1)):149-162 doi:10.1007/s00428-022-03432-2.

Follicle Center Lymphoma (FCL) of the Lower Female Genital Tract (LFGT): A Novel Variant of Primary Cutaneous Follicle Center Lymphoma (PCFCL).

Saksena A, Jain A, Pack SD, et al.

The American journal of surgical pathology 2023; (47(3)):409-419 doi:10.1097/PAS.0000000000002003.

Divergent paths: management of early relapsed follicular lymphoma.

Takiar R, Karimi Y, Phillips TJ

Hematology. American Society of Hematology. Education Program 2022; (2022(1)):666-675 doi:10.1182/hematology.2022000360.

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma.

Mohty R, Kharfan-Dabaja MA

Therapeutic advances in hematology 2022; (13()):20406207221142133 doi:10.1177/20406207221142133.

Managing Follicular Lymphoma in the Elderly Population.

Tan JJC, Sze YL, Choong Shi Hui C

Case reports in medicine 2023; (2023()):1038934 doi:10.1155/2023/1038934.

Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

Athni TS, Barmettler S

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Biological Data.

Kurz KS, Kalmbach S, Ott M, et al.

Cancers 2023; (15(3)) doi:10.3390/cancers15030785.

[Classification of indolent B-cell lymphomas : Novelties and open questions].

Anagnostopoulos I, Zamò A

Pathologie (Heidelberg, Germany) 2023; (44(3)):154-165 doi:10.1007/s00292-023-01186-5.

Divergent evolution of metachronous follicular lymphoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue from a common precursor.

Tzioni MM, Wotherspoon A, Chen Z, et al.

The Journal of pathology 2023; (261(1)):11-18 doi:10.1002/path.6143.

Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics.

Oishi N

Journal of clinical and experimental hematopathology : JCEH 2023; (63(2)):65-72 doi:10.3960/jslrt.23010.

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma.

Panjan M, Boltezar L, Novakovic S, et al.

Radiology and oncology 2023; (57(4)):487-492 doi:10.2478/raon-2023-0030.

Commentary on small-volume biopsy of follicular lymphoma: Practical issues in the molecular era.

Chen CC

Cancer cytopathology 2024; (132(3)):136-138 doi:10.1002/cncy.22742.

Gastrointestinal Follicular Lymphoma: A Single-institutional Experience of 22 Cases With Emphasis on the Comprehensive Clinicopathological Analysis and Diagnostic Re-classification.

Oh CH, Kim HS, DO SI, Na K

Anticancer research 2023; (43(9)):4089-4096 doi:10.21873/anticanres.16598.

Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study.

Tran QT, Nguyen Duy T, Nguyen-Tran BS, et al.

Diagnostics (Basel, Switzerland) 2023; (13(17)) doi:10.3390/diagnostics13172767.

[Treatment strategies for follicular lymphoma].

Fukuhara N

[Rinsho ketsueki] The Japanese journal of clinical hematology 2023; (64(9)):1019-1025 doi:10.11406/rinketsu.64.1019.

Predictive value of Dmax and %ΔSUVmax of 18F-FDG PET/CT for the prognosis of patients with diffuse large B-cell lymphoma.

Dang J, Peng X, Wu P, et al.

BMC medical imaging 2023; (23(1)):173 doi:10.1186/s12880-023-01138-8.

Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: Guidelines from the Groupe Francophone de Cytogénétique Hematologique (GFCH).

Lefebvre C, Veronese L, Nadal N, et al.

Current research in translational medicine 2023; (71(4)):103425 doi:10.1016/j.retram.2023.103425.

[Analysis of 9 cases of pediatric-type follicular lymphoma].

Li GP, Zhang D, Wang YQ, et al.

Zhonghua er ke za zhi = Chinese journal of pediatrics 2023; (61(12)):1129-1132 doi:10.3760/cma.j.cn112140-20230710-00002.

Surgical Lymph Node Biopsy for the Diagnosis of Lymphoma: A Case Report.

Wu CC, Leng E, Killeen TF, et al.

Cureus 2023; (15(11)):e49063 doi:10.7759/cureus.49063.

Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.

Dickinson M, Martinez-Lopez J, Jousseaume E, et al.

Leukemia & lymphoma 2024; (65(3)):323-332 doi:10.1080/10428194.2023.2289854.

ANALYSIS OF DIAGNOSTIC EXCISIONAL LYMPH NODE BIOPSY RESULTS: 12-YEAR EXPERIENCE OF A SINGLE CENTER.

Bayhan Z, Ozdemir K, Gonullu E, et al.

Acta clinica Croatica 2023; (62(1)):58-64 doi:10.20471/acc.2023.62.01.07.

Refractory chylous ascites revealing follicular lymphoma: A case report.

Tlili Y, Hadrich Z, Hafsi M, et al.

International journal of surgery case reports 2024; (116()):109414 doi:10.1016/j.ijscr.2024.109414.

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.

Barraclough A, Agrawal S, Talaulikar D, et al.

Haematologica 2024; (109(10)):3338-3345 doi:10.3324/haematol.2023.284538.

Recent advances in understanding the biology of follicular lymphoma.

Nishikori M

International journal of hematology 2025; (121(3)):326-330 doi:10.1007/s12185-024-03764-6.

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.

Watanabe T, Matsuno Y, Wakabayashi M, et al.

Hematological oncology 2024; (42(3)):e3272 doi:10.1002/hon.3272.

Advancements in the Management of Follicular Lymphoma: A Comprehensive Review

Merryman R, Mehtap Ö, LaCasce A

Turkish journal of haematology : official journal of Turkish Society of Haematology 2024; (41(2)):69-82 doi:10.4274/tjh.galenos.2024.2024.0015.

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.

Dobaño-López C, Valero JG, Araujo-Ayala F, et al.

Blood cancer journal 2024; (14(1)):75 doi:10.1038/s41408-024-01041-7.

Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution.

Lim S, Koh J, Bae JM, et al.

Diagnostic pathology 2024; (19(1)):86 doi:10.1186/s13000-024-01512-2.

Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

Tobin JWD, Hapgood G, Johnston A, et al.

Internal medicine journal 2024; (54(8)):1384-1395 doi:10.1111/imj.16454.

Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study.

Chan T, Champagne JN, Boudreault JS

Cureus 2024; (16(8)):e66124 doi:10.7759/cureus.66124.

Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy.

Cabrera ME, Peña C, Vega V, et al.

Cancer reports (Hoboken, N.J.) 2024; (7(9)):e2126 doi:10.1002/cnr2.2126.

[Transformation of Follicular Lymphoma into Composite Lymphoma: A Case Report and Literature Review].

Avilés-Salas A, Peña-Carvajalino LF, Heredia-Jara AN, et al.

Revista medica de Chile 2024; (152(4)):508-513 doi:10.4067/s0034-98872024000400508.

Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation.

Bosch-Schips J, Parisi X, Climent F, Vega F

Human pathology 2025; (156()):105676 doi:10.1016/j.humpath.2024.105676.

Follicular Lymphoma Presenting as a Primary Omental Mass: A Case Report and Pathological Analysis.

Raman S, Amitkumar K, Radhakrishnan B, Kumaran S

Cureus 2024; (16(11)):e73810 doi:10.7759/cureus.73810.

Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.

Luttwak E, Kumar A, Salles G

Leukemia & lymphoma 2025; (66(5)):818-829 doi:10.1080/10428194.2024.2447371.

CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL).

Stoevesandt D, Steglich J, Bartelt JM, et al.

Radiology 2025; (314(1)):e232650 doi:10.1148/radiol.232650.

Diagnosis and Classification of Follicular Lymphoma and Related Entities.

Laurent C, Cook JR

Advances in anatomic pathology 2025; (32(3)):195-207 doi:10.1097/PAP.0000000000000481.

Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment.

El Daker S, Qualls D, Derkach A, et al.

Haematologica 2025; (110(8)):1808-1821 doi:10.3324/haematol.2024.286383.

Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors.

Jóna Á, Kiss E, Illés Á

Diagnostics (Basel, Switzerland) 2025; (15(5)) doi:10.3390/diagnostics15050647.

Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.

Araujo-Ayala F, Béguelin W

Blood 2025; (146(15)):1759-1769 doi:10.1182/blood.2024026020.

Acceptance and commitment therapy effectiveness for fear of cancer recurrence: A systematic review and meta-analysis.

Yuyan Y, Jiaqi L, Ting W, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2025; (76()):102862 doi:10.1016/j.ejon.2025.102862.

Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.

Cheng S, Liu Y

Current treatment options in oncology 2025; (26(4)):313-330 doi:10.1007/s11864-025-01297-6.

Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.

Sun C, Li W, Yu J, et al.

Leukemia 2025; (39(6)):1425-1434 doi:10.1038/s41375-025-02603-9.

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

Gazeau N, Beauvais D, Tilmont R, et al.

Leukemia 2025; (39(7)):1714-1722 doi:10.1038/s41375-025-02605-7.

Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab.

Fealko CJ, Rolon-Newton MN, Aitken MJL, Gitlin SD

Case reports in neurology 2025; (17(1)):36-40 doi:10.1159/000544749.

The Role of Whole-Body MRI in Patients with Lymphoma: A Narrative Review.

Renzetti B, Cattabriga A, Brocchi S, et al.

Technology in cancer research & treatment 2025; (24()):15330338251359724 doi:10.1177/15330338251359724.

The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Kungwankiattichai S, Maziarz RT

Expert opinion on drug discovery 2025; (20(11)):1357-1368 doi:10.1080/17460441.2025.2567291.

Primary Splenic Follicular Lymphoma Presenting As Isolated Splenomegaly: A Case Report.

Indukuri P, Thomas S, Mehrotra P, Shanmugam SG

Cureus 2025; (17(10)):e93633 doi:10.7759/cureus.93633.

Assessing trends in conditional survival for non-Hodgkin lymphoma and chronic myeloid leukemia via novel extensions to the joinpoint survival model.

Devasia TP, Wheeler W, Buckman DW, et al.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2026; doi:10.1158/1055-9965.EPI-25-1199.

A hidden site: positron emission tomography-computed tomography (PET-CT) unveiling subclinical masseter involvement in follicular lymphoma - case report.

Ferchichi S, Guerbouj HK, Jouini Z, et al.

The Pan African medical journal 2025; (52()):96 doi:10.11604/pamj.2025.52.96.49728.

A rare diffuse follicular lymphoma with TP53 mutation and copy-neutral loss of heterozygosity at 1p36: insights into diagnosis, disease progression, and literature review.

Abdolahi M, Rungsiprakarn P, Lazim A, et al.

Journal of hematopathology 2026; (19(1)).